{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-384386","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2026-09-08T11:39:23+00:00","discovered_at":"2026-09-08T11:40:01.413036+00:00","generated_at":"2026-09-08T11:40:04.918887+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pyxis Oncology appoints Thomas Civik as permanent CEO and Chairman; Flavin becomes Lead Independent Director","bullets":["Civik, interim CEO since Feb 2026, named permanent CEO and Chairman effective Sept 4, 2026; Flavin transitions to Lead Independent Director.","New CEO package: $710k base salary, 60% target bonus, $100k sign-on bonus, and option for 2,503,050 shares vesting over 4 years.","Board member Santhosh Palani resigned Sept 4, 2026; board reduced from 8 to 7 members, with his unvested equity accelerated.","Company expects updated MICVO Phase 1 monotherapy data in 2L+ R/M HNSCC in Fall 2026 and Phase 1/2 combo data with pembrolizumab in Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-384386","json":"https://secwatch.observer/filing/0001193125-26-384386.json","markdown":"https://secwatch.observer/filing/0001193125-26-384386.md","text":"https://secwatch.observer/filing/0001193125-26-384386.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526384386/0001193125-26-384386-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000119312526384386/pyxs-20260903.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T11:40:04.918887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}